Evidence map›Paper›PMID 35088080›Full record

ArticleHuman molecular genetics2022

Identification of the genetic mechanism that associates L3MBTL3 to multiple sclerosis.

Antonio Alcina, Maria Fedetz, Isabel Vidal-Cobo, Eduardo Andrés-León, Maria-Isabel García-Sánchez, Alicia Barroso-Del-Jesus, Sara Eichau, Elia Gil-Varea, Luisa-Maria Villar, Albert Saiz and 7 more

Open access · hybridAbstract read
In one paragraph

Article in Human molecular genetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 11 institutions in 1 country.

Antonio AlcinaDepartment of Cell Biology and Immunology, Instituto de Parasitología y Biomedicina "López Neyra", Consejo Superior de Investigaciones Científicas (IPBLN-CSIC) 18016 Granada, Spain.ORCID 0000-0001-7294-0948
Maria FedetzDepartment of Cell Biology and Immunology, Instituto de Parasitología y Biomedicina "López Neyra", Consejo Superior de Investigaciones Científicas (IPBLN-CSIC) 18016 Granada, Spain.
Isabel Vidal-CoboDepartment of Cell Biology and Immunology, Instituto de Parasitología y Biomedicina "López Neyra", Consejo Superior de Investigaciones Científicas (IPBLN-CSIC) 18016 Granada, Spain.
Eduardo Andrés-LeónBioinformatic Unit, Instituto de Parasitología y Biomedicina López Neyra (IPBLN-CSIC), 18016 Granada, Spain.ORCID 0000-0002-0621-9914
Maria-Isabel García-SánchezUGC Neurología, Nodo Hospital Universitario Virgen Macarena, Biobanco del Sistema Sanitario Público de Andalucía, 41009 Sevilla, Spain.
Alicia Barroso-Del-JesusGenomics Unit, Instituto de Parasitología y Biomedicina López Neyra (IPBLN-CSIC), 18016 Granada, Spain.
Sara EichauUGC Neurología, Hospital Universitario Virgen Macarena, 41009 Sevilla, Spain.
Elia Gil-VareaServei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona 08035, Spain.
Luisa-Maria VillarDepartments of Immunology, Hospital Ramon y Cajal, (IRYCIS), 28034 Madrid, Spain.
Albert SaizServicio de Neurología, Hospital Clinic and Institut d'Investigació Biomèdica Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, 08036 Barcelona, Spain.
Laura LeyvaInstituto de Investigación Biomédica de Málaga-IBIMA, UGC Neurología, Hospital Regional Universitario de Málaga, Málaga 29010, Spain.
Koen VandenbroeckInflammation & Biomarkers Group, Biocruces Bizkaia Health Research Institute, Barakaldo 48903, Spain.
David OtaeguiNeurosciences Area, Biodonostia Health Research Institute, 20014 San Sebastián, Spain.
Guillermo IzquierdoMultiple Sclerosis Unit, Neurology Service, Vithas Nisa Hospital, Seville 41950, Spain.
Manuel ComabellaServei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona 08035, Spain.
Elena UrcelayLab. of Genetics of Complex Diseases, Hospital Clinico San Carlos, Instituto de Investigacion Sanitaria San Carlos (IdISSC), Madrid 28040, Spain.
Fuencisla MatesanzDepartment of Cell Biology and Immunology, Instituto de Parasitología y Biomedicina "López Neyra", Consejo Superior de Investigaciones Científicas (IPBLN-CSIC) 18016 Granada, Spain.ORCID 0000-0002-9429-1819
Consejo Superior de Investigaciones Científicas · ESHospital Universitario Virgen Macarena · ESInstituto de Parasitología y Biomedicina "López - Neyra" · ESUniversitat Autònoma de Barcelona · ESBiogipuzkoa Health Research Institute · ESConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESHospital Regional Universitario de Málaga · ESIkerbasque · ESInstituto de Investigación Sanitaria del Hospital Clínico San Carlos · ESInstituto Ramón y Cajal de Investigación Sanitaria · ESSpanish Multiple Sclerosis Network · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple sclerosis (MS) is a complex and demyelinating disease of the central nervous system. One of the challenges of the post-genome-wide association studies (GWAS) era is to understand the molecular basis of statistical associations to reveal gene networks and potential therapeutic targets. The L3MBTL3 locus has been associated with MS risk by GWAS. To identify the causal variant of the locus, we performed fine mapping in a cohort of 3440 MS patients and 1688 healthy controls. The variant that best explained the association was rs6569648 (P = 4.13E-10, odds ratio = 0.71, 95% confidence interval (CI) = 0.64-0.79), which tagged rs7740107, located in intron 7 of L3MBTL3. The rs7740107 (A/T) variant has been reported to be the best expression and splice quantitative trait locus (eQTL and sQTL) of the region in up to 35 human genotype-tissue expression (GTEx) tissues. By sequencing RNA from blood of 17 MS patients and quantification by digital qPCR, we determined that this eQTL/sQTL originated from the expression of a novel short transcript starting in intron 7 near rs7740107. The short transcript was translated into three proteins starting at different translation initiation codons. These N-terminal truncated proteins lacked the region where L3MBTL3 interacts with the transcriptional regulator Recombination Signal Binding Protein for Immunoglobulin Kappa J Region which, in turn, regulates the Notch signalling pathway. Our data and other functional studies suggest that the genetic mechanism underlying the MS association of rs7740107 affects not only the expression of L3MBTL3 isoforms, but might also involve the Notch signalling pathway.

Indexed as

Genome-Wide Association StudyMultiple SclerosisDNA-Binding ProteinsGenetic Predisposition to DiseaseHumansPolymorphism, Single NucleotideQuantitative Trait LociDNA-Binding ProteinsL3MBTL3 protein, human

Identifiers

PMID35088080
PMCPMC9262392
OpenAlexW4210731411

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.